drugset / Trial / NCT01550900
Prospective Trial of Metformin - Chemoprevention Role
Withdrawn
M.D. Anderson Cancer Center
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this clinical research study is to learn if metformin extended release (ER) can prevent colonic adenomas from becoming cancerous. Metformin ER will be compared to a placebo. Metformin ER is designed to block a protein in tumor cells that is important in tumor growth and blood vessel development. This may cause cell death or reduce the spread of the disease. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
Timeline
- Start
- 2013-07
- Primary completion
- 2020-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 1000 mg | Oral |